The CATT (Comparison of Age-related Macular Degeneration Treatments Trials) study compared ranibizumab versus bevacizumab for neovascular AMD. Which finding was clinically most significant at 2 years?
- A Ranibizumab was superior to bevacizumab in visual acuity gain
- B Both agents were equivalent in visual acuity outcomes; as-needed dosing was inferior to monthly ✓
- C Bevacizumab had significantly more systemic adverse events
- D Monthly regimen gave same outcomes as PRN with both agents
Explanation
The CATT trial demonstrated that ranibizumab and bevacizumab were equivalent in visual acuity outcomes at 2 years (non-inferiority confirmed). However, as-needed (PRN) dosing was inferior to monthly dosing by approximately 2 letters of visual acuity. Serious systemic adverse events were slightly higher with bevacizumab (arteriothrombotic events), though the difference was not statistically significant. The HARBOR trial later showed that 0.5 mg ranibizumab monthly was not inferior to 2.0 mg, establishing the standard dose. These trials established anti-VEGF as standard of care for neovascular AMD.
Reference: Khurana Comprehensive Ophthalmology, 7th ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.